KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency: a randomized phase 3 study.

Maria Fleseriu, Beverly M K Biller, Susan M Webb, Christian J Strasburger, Carmen E Georgescu, Martin Bidlingmaier, Christina Wang, Ionela Baciu, Felipe F Casanueva, Aleksandra Gilis-Januszewska, Gili Hart, Allison Manners, John Choe, Ahuva Bar-Ilan, Martin Carlsson, Daria La Torre, Carrie Turich Taylor, Kevin C J Yuen

Pituitary 29(2) 59

PMID41879875
PMCIDPMC13017995
DOI10.1007/s11102-026-01661-1
发表日期2026-03-25
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:图注未提示 KM 曲线;Fig. 2:身体组成变化图;Fig. 3:身体组成变化图。
摘要

摘要

PURPOSE: This study assessed the efficacy and safety of once-weekly somatrogon, a long-acting growth hormone, in adults with growth hormone deficiency (aGHD). METHODS: A phase 3 randomized, double-blind, placebo-controlled study consisted of a 26-week double-blind period (Period 1), a 26-week open-label extension (OLE; Period 2), and a multi-year OLE (Period 3). Patients were randomized 2:1 to somatrogon or placebo in Period 1, with dosing adjusted for gender, age, and estrogen therapy. All patients received somatrogon in Periods 2 and 3. Primary endpoint was change in trunk fat mass (FM; baseline-Week 26). Secondary endpoints included changes in total FM, lean body mass (LBM), percentage change in trunk FM, and trunk FM. Changes in percent trunk FM relative to total trunk mass (FM + LBM), trunk LBM, and appendicular skeletal muscle mass were also evaluated in a post-hoc supplemental analysis. Safety assessments included adverse events (AEs) and laboratory evaluations. RESULTS: Of 389 patients screened, 202 were randomized, and 198 received treatment (somatrogon:133; placebo:65). Mean IGF-I SDS normalized following somatrogon initiation. There was no significant difference between somatrogon and placebo in change in trunk FM from baseline to Week 26 (-0.37 vs 0.03 kg; p=0.0821; primary endpoint) or in total FM. However, somatrogon significantly improved LBM, trunk FM as a percentage of total FM and the three supplemental endpoints. AE incidence was similar between groups, with most being mild to moderate in severity. CONCLUSION: Somatrogon significantly improved several body composition parameters and was well tolerated overall in adults with GHD. CLINICALTRIALS.GOV: NCT01909479; registration date: 25/07/2013

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Patient disposition. LT-OLE=long-term open-label extension
非 KM Figure
Fig. 2Primary and secondary endpoints of efficacy analysis. LSMs and P-value for comparison between somatrogon and placebo are from a mixed model for repeated measures (MMRM), where n represents the number of randomized patients included in the MMRM. FM = fat mass; LBM=lean body mass; LSM=least squares mean
非 KM Figure
Fig. 3Supplemental efficacy analysis. ASMM=appendicular skeletal muscle mass; CI=confidence interval; FM = fat mass; LBM=lean body mass; LSM=least squares mean
非 KM Figure